Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A R Zander

Showing results (211-220 of 225) with videos related to

Pageof 23
Sort By:
Annals of Hematology|March 4, 2003
Reduced non-relapse mortality after reduced intensity conditioning in advanced chronic lymphocytic leukemiaJ Schetelig, C Thiede, M Bornhäuser, et al.
Bone Marrow Transplantation|June 21, 2006
Retroviral vector insertions in T-lymphocytes used for suicide gene therapy occur in gene groups with specific molecular functionsF A Giordano, B Fehse, A Hotz-Wagenblatt, et al.
Annals of Hematology|July 20, 2000
ASHAP--an effective salvage therapy for recurrent and refractory malignant lymphomasM Hänel, N Kröger, M M Hoffknecht, et al.
Leukemia|February 23, 2011
Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemiaC Craddock, M Labopin, S Pillai, et al.
Bone Marrow Transplantation|October 24, 2000
Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemiaN Kröger, T Zabelina, S Sonnenberg, et al.
Bone Marrow Transplantation|August 6, 2003
ATG as part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patients with chronic myelogenous leukemia (CML)A R Zander, N Kröger, M Schleuning, et al.
Bone Marrow Transplantation|January 7, 1999
Intensified conditioning regimen in bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemiaN Kröger, W Krüger, G Wacker-Backhaus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 1999
High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remissionA R Zander, C Berger, N Kröger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2003
Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study GroupJ Schetelig, C Thiede, M Bornhauser, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2004
High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trialA R Zander, N Kröger, C Schmoor, et al.
Pageof 23

Showing results (211-220 of 225) with videos related to

Sort By:
Pageof 23
Annals of Hematology|March 4, 2003
Reduced non-relapse mortality after reduced intensity conditioning in advanced chronic lymphocytic leukemiaJ Schetelig, C Thiede, M Bornhäuser, et al.
Bone Marrow Transplantation|June 21, 2006
Retroviral vector insertions in T-lymphocytes used for suicide gene therapy occur in gene groups with specific molecular functionsF A Giordano, B Fehse, A Hotz-Wagenblatt, et al.
Annals of Hematology|July 20, 2000
ASHAP--an effective salvage therapy for recurrent and refractory malignant lymphomasM Hänel, N Kröger, M M Hoffknecht, et al.
Leukemia|February 23, 2011
Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemiaC Craddock, M Labopin, S Pillai, et al.
Bone Marrow Transplantation|October 24, 2000
Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemiaN Kröger, T Zabelina, S Sonnenberg, et al.
Bone Marrow Transplantation|August 6, 2003
ATG as part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patients with chronic myelogenous leukemia (CML)A R Zander, N Kröger, M Schleuning, et al.
Bone Marrow Transplantation|January 7, 1999
Intensified conditioning regimen in bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemiaN Kröger, W Krüger, G Wacker-Backhaus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 1999
High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remissionA R Zander, C Berger, N Kröger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2003
Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study GroupJ Schetelig, C Thiede, M Bornhauser, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2004
High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trialA R Zander, N Kröger, C Schmoor, et al.
Pageof 23